In GH-deficient children, added leuprolide reduced bone age maturation to 1.5 +/- 0.2 yr versus 4.2 +/-0.5 yr with GH alone.
In plain wordsIn GH-deficient children, added leuprolide reduced bone age maturation compared with GH alone.
- Peptide
- Leuprolide
- Outcome
- DecreaseBone age maturation
- Study
n = 17
- Comparator
- GH alone
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 300 microg/kg every 28 days · 3 yrAs given in this study (human).
Measurements
- Bone age maturation rate
- 1.5 yr
- GH + LHRH-A, +/- 0.2, during 3 years of LHRH-A therapy
- Bone age maturation rate
- 4.2 yr
- GH alone, +/- 0.5, during the same 3 years
Source sentences
We observed a significant decrease in the rate of BA maturation in the group treated with GH+LHRH-A (1.5 +/- 0.2 yr) compared with the group treated with GH alone (4.2 +/-0.5 yr) during the 3 years of LHRH-A therapy (P < 0.05).
2 context sentences(design, population, supporting numbers)
Patients were randomly assigned to receive GH + LH-releasing hormone analog (LHRH-A) (n = 7), or GH alone (n = 10).
GH (Nutropin) was administered at a dose of 0.1 U/kg x day sc, until patients reached a bone age (BA) of 14 yr in girls and 16 yr in boys, and LHRH-A (Lupron depot) was administered at a dose of 300 microg/ kg every 28 days in during 3 yr.